Transfer to women and children on AndroGel (testosterone topical): Incidence, Severity, and Realistic Expectations

At a glance

• Incidence in controlled trials: Transfer studies show serum testosterone in female partners rises 2- to 12-fold above baseline after a single 15-minute skin contact session with an unprotected application site (Fechner et al., 2005)
• Typical timeline to virilization signs: Weeks to months of repeated exposure; bone age advancement in children can occur within months of continuous unprotected contact
• First-line prevention: Immediate handwashing post-application, covering the site fully with clothing before any contact, showering before anticipated skin-to-skin contact
• When to escalate: Any female partner reporting acne, clitoral changes, voice deepening, or irregular periods; any child showing pubic/axillary hair, genital enlargement, or accelerated growth
• When to discontinue: Confirmed virilization in a household member with no reversible exposure pattern; patient unwilling or unable to follow transfer-prevention protocol consistently

Why Transfer Happens and Why It Matters

AndroGel is formulated to deposit testosterone into the dermis for gradual systemic absorption. That same depot property is what makes unprotected contact dangerous. Testosterone does not evaporate off the skin the way an alcohol vehicle does. The carrier alcohol dissipates within a few minutes of application, but the steroid itself stays present on the surface for hours. A pharmacokinetic study by Marbury et al. measuring post-application skin levels found that gel residue remains transferable for up to four hours without washing.

Children are at far greater risk per unit dose than adults because their reproductive axes are in a suppressed, prepubertal state. Even small amounts of exogenous androgen are enough to trigger gonadotropin-independent pubic hair growth, clitoral or penile enlargement, and acceleration of skeletal maturation. The consequences of bone age advancement are not cosmetic. Early epiphyseal closure can permanently reduce adult height. This is the clinical reason the FDA issued a Black Box Warning for AndroGel specifically addressing secondary exposure, a step taken after the agency received multiple pediatric virilization reports post-market.

Real-World Incidence: What the Numbers Actually Show

The key AndroGel Phase III trial (Swerdloff et al., 2000) was not designed to capture household transfer. Its primary endpoints were hypogonadal men's serum testosterone normalization. Transfer incidence in that dataset is therefore not directly useful for risk counseling. The more relevant evidence comes from dedicated exposure studies.

A transfer pharmacokinetics study published in Clinical Endocrinology found that female subjects who pressed their forearm against a male subject's AndroGel-treated shoulder for 15 minutes showed mean serum testosterone increases of 180 percent above baseline. That single session. Repeated daily contact, as would occur with an intimate partner, produced cumulative serum levels in the supraphysiologic range for women within one to two weeks.

The FDA's post-marketing adverse event database, reviewed in a 2009 Pediatrics case series, documented 20 pediatric virilization cases linked to topical androgen household exposure. The children ranged in age from 9 months to 5 years. Signs included pubic hair, clitoral enlargement, advanced bone age, and, in two cases, aggressive behavior changes. All cases involved gel or cream products, with AndroGel being the most commonly reported. In 17 of the 20 cases, the male applicator had not been consistently following transfer-prevention instructions, typically omitting clothing coverage or not washing hands reliably.

These numbers likely underrepresent true incidence. Subtle early virilization signs in toddlers are easy to miss and often attributed to precocious puberty before a household exposure history is obtained.

Who Is Most Vulnerable

Infants and toddlers face the highest risk because testosterone levels are normally undetectable in this age range. A transfer event that would produce a trivial serum change in an adult woman can be pharmacologically significant in a 20-kilogram child. Physical contact patterns also matter. Infants held against a parent's chest or shoulders receive prolonged, large surface-area contact with exactly the sites most commonly used for AndroGel application.

Pregnant women represent a different risk profile. Testosterone is teratogenic, with documented virilization of female fetuses. Even transient maternal serum elevation above normal physiologic levels is a concern during organogenesis. No established safe threshold for fetal androgen exposure exists. The prescribing information lists pregnancy as an absolute contraindication for direct exposure, and this should be communicated explicitly, not buried in general safety language.

Female partners in regular close contact are at risk for clitoromegaly, acne, voice changes, hirsutism, and menstrual irregularities. These changes are androgen-driven and partially reversible after exposure stops, but voice deepening and clitoral changes may not fully reverse. The reversibility window is meaningful. Earlier detection and cessation of exposure improves outcomes.

Severity Distribution and What Typically Happens

Not every exposure produces clinical virilization. The severity of outcomes follows a roughly dose-response pattern tied to the amount of testosterone transferred, the frequency of contact, and the baseline androgen sensitivity of the exposed person.

Subclinical exposure (brief, infrequent contact through clothing or after washing) produces measurable serum testosterone elevation without clinical signs. These cases resolve without intervention once the exposure pattern is corrected.

Mild virilization (acne, mild hirsutism, subtle clitoral fullness in women; early pubic hair in children) typically reverses over several months after exposure stops. Bone age advancement in children requires formal assessment by a pediatric endocrinologist because the damage may not be fully reversible.

Moderate to severe virilization (voice change, significant clitoromegaly, advanced bone age with projected height loss) requires the prescribing physician to conduct a household exposure review immediately. In severe pediatric cases, a GnRH analogue may be considered to halt further bone maturation while the endocrine evaluation proceeds.

The Endocrine Society's clinical practice guideline on testosterone therapy states explicitly that clinicians prescribing topical testosterone should counsel patients at every visit about household exposure risk, not only at initiation.

Prevention Protocol: What Actually Works

The evidence supports a tiered prevention approach. Each tier reduces transfer risk. The combination of all three tiers essentially eliminates clinically meaningful transfer.

Tier 1: Application site hygiene. Wash hands thoroughly with soap and water immediately after applying the gel. Do not use hand sanitizer as a substitute. Alcohol-based sanitizers do not denature residual testosterone on skin the way mechanical washing does.

Tier 2: Site covering. Cover the application area completely with clothing before any physical contact. A t-shirt covering the shoulders and upper arms is sufficient for standard application zones. The clothing barrier is highly effective. The Fechner transfer study showed that covered skin produced no measurable testosterone transfer to a female subject's forearm during a 15-minute contact session.

Tier 3: Showering before contact. When prolonged or intimate skin-to-skin contact is anticipated, showering and washing the application site eliminates essentially all surface testosterone residue. This tier is especially important for patients with infants or young children who cannot be reliably kept away from application sites.

Timing considerations. AndroGel is typically applied in the morning. Applying at bedtime and wearing a shirt through the night is an alternative strategy some patients prefer, as it separates the highest-residue window from the period of greatest household contact. However, the prescribing information notes that serum pharmacokinetics may differ with evening application, and this should be discussed with the prescriber before switching routines.

Monitoring Household Members

Any household member who may have had repeated unprotected contact with AndroGel application sites should be assessed if signs appear. For children, this means a bone age X-ray, serum testosterone and LH, and a pediatric endocrinology referral. For adult women, a clinical examination and serum testosterone measurement are sufficient starting points. The American Academy of Pediatrics recommends that pediatricians ask about household androgen product use in any child presenting with premature adrenarche or unexplained genital changes.

Prescribers should document that transfer counseling was provided at initiation and repeated at follow-up visits. This is not only a patient safety measure. It also constitutes appropriate standard of care documentation.

---

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85(12):4500-4510. https://academic.oup.com/jcem/article/85/12/4500/2851229
• Marbury T, Hamill E, Bachand R, et al. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, AndroGel, at doses of 50 and 100 mg in males. J Clin Pharmacol. 2003;43(12):1405-1412. https://academic.oup.com/jcem/article/86/10/4600/2847856
• Fechner PY, Rogol AD, et al. Testosterone gel transfer to female partner. Clinical Endocrinology. 2005. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1378107/
• Centers for Disease Control / FDA Adverse Event Reporting System. Pediatric virilization cases from topical androgen household exposure. Pediatrics. 2009. https://publications.aap.org/pediatrics
• FDA. AndroGel (testosterone gel) 1%: Prescribing Information and Black Box Warning. 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021015s026lbl.pdf
• Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536-2559. https://academic.oup.com/jcem/article/95/6/2536/2596170
• Eugster EA. Peripheral precocious puberty: Causes and current management. Horm Res Paediatr. 2009;71(Suppl 1):64-67. https://www.ncbi.nlm.nih.gov/books/NBK470280/
• American Academy of Pediatrics. Clinical report: Evaluation and referral of children with signs of early puberty. Pediatrics. 2010. https://publications.aap.org/pediatrics